Last updated: April 25, 2026
ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J.) — Litigation Summary and Patent/ANDA Analysis (Civ. No. 2:16-cv-07721)
What is the case and what claims were at issue?
- Case caption: ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC.
- Court / docket: U.S. District Court for the District of New Jersey (D.N.J.), Civil Action No. 2:16-cv-07721
- Core posture: Patent infringement litigation arising from a generic product entry path under the Hatch-Waxman framework (ANDA-driven infringement and invalidity/defense themes are typical for this docket class).
What relief did the plaintiff seek?
In ANDA patent cases in the District of New Jersey under the usual 35 U.S.C. § 271(e)(2) structure, the plaintiff typically seeks:
- A judgment of infringement as to one or more asserted patents,
- Injunctive relief to prevent FDA approval or launch during the statutory stay/eligibility period when infringement is found (subject to the act’s procedural limits),
- Damages (including for the period of infringing commercial manufacture or sale where legally available).
(Exact claims and requested relief language are docket- and filing-dependent; no pleadings or specific asserted-patent identifiers are provided in the input.)
Which patents were asserted, and what were the infringement theories?
What patents were involved?
No asserted patent numbers, expiration dates, ownership chain, or claim construction results were provided in the input. Without those specifics, an accurate element-by-element infringement mapping and validity analysis cannot be produced.
What infringement theories were likely used?
Where the plaintiff alleges infringement in an ANDA case, the infringement theories are commonly one or more of the following:
- Direct infringement of the claimed dosage form or formulation in the ANDA-manufactured product as described in the ANDA label/specifications.
- Method-of-use infringement tied to the proposed Indications/labeling for the ANDA product.
- Contributory/indirect infringement themes are also common but depend on the patents asserted.
No asserted claim categories are included in the prompt, so the theory mix cannot be stated as fact.
How did Teva defend the case?
What invalidity and non-infringement defenses are typical in this posture?
In comparable D.N.J. ANDA litigations, defendants typically raise a combination of:
- Non-infringement based on differences between the asserted claims and the proposed product characteristics.
- Invalidity including:
- Anticipation/obviousness based on prior art references,
- Lack of written description or enablement (for formulation or method claims),
- Indefiniteness under 35 U.S.C. § 112,
- Patent-ineligible subject matter arguments (where applicable) under § 101.
- Procedural defenses tied to ANDA notice and statutory timing.
No specific defense filings, grounds, or claim-by-claim validity rulings are present in the input.
What happened procedurally in the case?
What are the key procedural milestones?
No scheduling orders, claim construction dates, summary judgment rulings, settlement orders, jury trial outcomes, or appeal docket entries were included in the prompt.
As a result, the procedural timeline cannot be stated with the required specificity (for example: “Markman held on X,” “summary judgment on Y,” “stipulated dismissal with prejudice on Z”) without the missing docket record.
What does the case mean for ADAPT’s IP strategy?
How should IP ownership and claim scope be evaluated?
For business decision-making in formulation and product-lifecycle cases, the litigation’s business value typically lies in:
- Claim scope held during claim construction (often dispositive for validity and infringement leverage),
- Court’s view on novelty and obviousness (prior art mapping and motivation-to-combine findings),
- Whether the plaintiff secured an injunction or early termination (which drives generic market exclusion value),
- Whether Teva’s proposed product design-around was deemed non-infringing.
No claim construction, validity holdings, or final disposition facts are available in the input; no court holdings can be asserted.
What does the case mean for Teva and launch timing?
How does an ANDA patent case translate to commercial risk?
In practice, generic risk is driven by:
- Whether the litigation ended in a final merits ruling (stronger for both value transfer and design-around clarity),
- Whether any stipulations or partial settlements were entered (common path to staggered launch),
- Whether the court entered an order affecting FDA approval timing.
The input does not include the final judgment type (dismissal, settlement, consent judgment, merits win/loss), so launch impact cannot be concluded as fact.
Litigation Outcome and Disposition
How did the court resolve the case?
No final disposition details are provided in the prompt (for example: “settled,” “dismissed without prejudice,” “summary judgment granted,” “consent judgment entered,” or “trial verdict”).
Because outcome determines licensing and market exclusivity implications, the absence of this information prevents a complete and accurate analysis.
Key Takeaways
- Case identity and docket: ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC., D.N.J. Civ. No. 2:16-cv-07721.
- Business-critical elements missing from the provided record: asserted patent numbers, claim categories, infringement/validity claim charts, claim construction results, procedural milestones, and final disposition.
- Without those facts, no defensible patent landscape or infringement/validity evaluation can be stated.
FAQs
-
What court handled ADAPT PHARMA v. TEVA (2:16-cv-07721)?
The U.S. District Court for the District of New Jersey (D.N.J.).
-
Is this an ANDA Hatch-Waxman patent infringement case?
The docket number class provided aligns with patent litigation typically tied to ANDA entry, but no ANDA-specific facts are included in the prompt.
-
Which patents were asserted?
Asserted patent numbers are not provided in the input, so they cannot be listed as fact.
-
What was the litigation outcome?
The final disposition is not included in the input, so the outcome cannot be stated as fact.
-
What is the commercial impact on generic launch timing?
Commercial impact depends on the final ruling or settlement terms; those terms are not included in the prompt.
References
[1] ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC., D.N.J. Civ. Action No. 2:16-cv-07721 (case caption and docket number as provided).
